Company Profile

Syracuse Biolabs Inc
Profile last edited on: 3/3/2022      CAGE: 7BEU5      UEI: QAW2G2NJY562

Business Identifier: Facilitating commercial development of early stage biochemical based technologies: diagnostics, biosensing, therapeutics and medical technology.
Year Founded
2014
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

841 East Fayette Street
Syracuse, NY 13210
   (315) 427-3441
   N/A
   N/A
Location: Single
Congr. District: 24
County: Onondaga

Public Profile

Syracuse Biolabs (SBL) is an early stage biotechnology firm leveraging internal expertise and partnering with academic and contract laboratories to drive novel medical and biotechnology from early stage funding through commercialization. SBL has access to state-of-the art research facilities and core equipment needed to advance innovative medical and biotechnological products from proof-of-concept to commercialization. Previous projects tackled by SBI personnel have included Efficient, Fieldable DNA Purification Modules: technology toadvance a novel workflow and device for separation and recovery of human & plant DNA from complex samples for downstream DNA sequencing applications. Field of use: forensics, plant genetics, detection of biological agents (i.e. bacteria, viruses) Technology Readiness Level (TRL): 3; Mobile BSL 2 Labs for Virus Detection Technology Overview: Mobile BSL 2 labs being developed in response to the existing COVID-19 pandemic and future viral outbreaks - aimed at supporting existing and future demand for rapid, onsite virus detection using validated rt-PCR assays. Labs deployed for dedicated assay work to enable high throughout analysis and detection of a desired biological target (i.e. bacteria, virus). Mobile BSL 2 Labs will meet all state and federal specifications for CLIA approval. Field of use: detection of biological agents (i.e. bacteria, viruses) , COVID-19 detection Technology Readiness Level (TRL): 5. Nanopore-Based Sensor Technology for rapid DNA Analysis - aimed to advance a highly novel method to rapidly analyze DNA fragments for detection of biological organisms. System consists of a novel nanopore microarrary sensor hardware to allow for rapid, parallel analysis of DNA fragments. Sensor hardware will be supported by proprietary software with DNA analysis capabilities enabling classification of detected biological targets. Field of use: detection of biological agents (i.e. bacteria, viruses) Technology Readiness Level (TRL): 1 Instant Anti-Infection Wound Care Dressing : This hydrogel material, from its dry state, can absorb enormous amount of aqueous solution, and incorporate materials with desired functions without toxicity issues. Such functions include 1) clotting of blood component to assist the natural hemostatic to stop the blood, 2) to prevent microbial growth or to kill bacteria and create a naturally sterile condition, 3) to soak up the secretion from the wound sites without binding to the regenerating growing tissue, and 4) to provide agents to assist a fast wound healing. While hemostatic agents exist in the market, the development of a functional hydrogel that provide a combined list of these functions is lacking. Field of use: wound dressing in the field Technology Readiness Level (TRL): 8. GLYCOBLOCK™ : COVID-19 Neutralizing Mask Boosting Spray: innovative mask spray contains GLYCOBOCK™, a natural surfactant that has been shown to bind COVID-19 Spike protein and inhibit viral entry into human cell. SARs-CoV-2 model studies using GLYCOBLOCK™ demonstrated 95% neutralizing of the virus. This mask spray is non-toxic, alcohol free, gluten free and contains all natural ingredients. More information can be found at www.glycoblock.com Field of use: neutralizing of SARs-CoV-2 virus (COVID-19) on masks and PPE material Technology Readiness Level (TRL): 9Located in the CNY Bio

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $218,846
Project Title: A novel method for improved separation of metagenomic samples for preservation and identification.

Key People / Management

  Mark McPike -- President

  Michael Marciano

Company News

There are no news available.